Violation of drugs patents: Boehringer Ingelheim demands mechanisms in place
Advertisement
Drug major Boehringer Ingelheim India has urged authorities to put in place a system that will inform patent holders whenever an application is filed by local brands for generic versions of patented molecules. The demand of the company, which is part of Germany's privately-held Boehringer Ingelheim, also comes at a time when there are rising concerns over patent infringements and copyright violations in various sectors, including the fast growing pharma space.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.